1. Home
  2. ADAM vs GERN Comparison

ADAM vs GERN Comparison

Compare ADAM & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ADAM

Adamas Trust Inc.

N/A

Current Price

$7.29

Market Cap

634.9M

Sector

Technology

ML Signal

N/A

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.38

Market Cap

753.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADAM
GERN
Founded
2003
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
634.9M
753.3M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
ADAM
GERN
Price
$7.29
$1.38
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$7.50
$3.00
AVG Volume (30 Days)
751.3K
7.0M
Earning Date
02-18-2026
11-05-2025
Dividend Yield
12.62%
N/A
EPS Growth
N/A
N/A
EPS
0.19
N/A
Revenue
$216,781,000.00
$183,403,000.00
Revenue This Year
$13.60
$147.42
Revenue Next Year
$49.42
$39.42
P/E Ratio
$37.63
N/A
Revenue Growth
N/A
522.13
52 Week Low
$5.02
$1.04
52 Week High
$7.75
$3.68

Technical Indicators

Market Signals
Indicator
ADAM
GERN
Relative Strength Index (RSI) N/A 58.64
Support Level N/A $1.30
Resistance Level N/A $1.37
Average True Range (ATR) 0.00 0.08
MACD 0.00 0.00
Stochastic Oscillator 0.00 68.75

Price Performance

Historical Comparison
ADAM
GERN

About ADAM Adamas Trust Inc.

Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing and managing primarily mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit sensitive single-family and multi-family assets.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: